The complexity and variability of OSCC and the relatively high number of person-specific factors involved in recurrence onset does not allow to define a single type of patient and consequently a uniform treatment approach. Therefore OraMod – keeping the patient as the center of the care delivery process – produces a patient-specific risk stratification and allows clinicians to adopt personalized care delivery, depending on disease manifestation and phenotypization.
The typical application scenario foresees two main steps: “pre-surgical risk stratification”, when the patient is diagnosed, in order to better plan primary treatment and a “post-treatment risk re-assessment” when the clinician must decide the follow-up to be administered for the patient. Clinicians will get access to OraMod via a secure portal to manage patient’s data, to execute the predictive model and to discuss patient’s case through the “Virtual Tumor Board”.
The patient’s data warehouse is fed by data from the Hospital Information Systems (HIS) and from the Hospital PACS via a push service. Already collected data will therefore be available to the clinicians. Patients’ data will be pseudonymized/ anonymized and semantically annotated.
Clinicians may use the OraMod simulation tools to further verify the model suggestions regarding risk of disease reoccurrence, by including into the model data from their experience and from clinical guidelines. This will allow better informed decision-making and personalized tailoring of patients’ therapy and follow-up.
Patients will be able to be informed at any follow-up regarding their prognosis with more accurate precision than today.
Patients at higher risk of disease reoccurrence will receive a more strict follow-up, while patients at low risk will follow golden standard follow-up pathways and avoid unnecessary post-surgery treatments (i.e. chemo-therapy).